PharmaTimesNews & Politicsnews

Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy

Wednesday, July 8, 2026John PinchingView original

SEGRAM aims to offer an alternative to glucocorticoid‑based treatment

Read the full article on the original site.

Read Full Article